Michael Ulz
Stock Analyst at Morgan Stanley
(3.71)
# 662
Out of 4,829 analysts
119
Total ratings
45%
Success rate
9.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $3.70 | +575.68% | 12 | May 9, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $27.55 | +270.24% | 3 | Apr 24, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $284 → $268 | $251.15 | +6.71% | 10 | Apr 11, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $2.11 | +847.87% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $1.19 | +1,748.74% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $10.45 | +177.51% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $3.89 | +79.95% | 7 | Mar 5, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $75 → $54 | $6.02 | +797.76% | 5 | Mar 3, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $1.75 | +1,042.86% | 4 | Feb 28, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Equal-Weight | $20 → $5 | $5.15 | -2.91% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.62 | +517.28% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $39.85 | +140.90% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $11.41 | +355.74% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $110 → $115 | $97.17 | +18.35% | 9 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $44.27 | +28.76% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $13.03 | +107.21% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.04 | +573.08% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $32.30 | +48.63% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $5.08 | +431.50% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $3.26 | +513.50% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.99 | +543.78% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.71 | +1,308.45% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $0.33 | +2,339.02% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $2.13 | +40.85% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.09 | +489.97% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $1.13 | +2,554.87% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $6.67 | +575.17% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $0.32 | +6,171.56% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $35.11 | +127.86% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $5.99 | +150.63% | 3 | Jul 12, 2017 |
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $3.70
Upside: +575.68%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $27.55
Upside: +270.24%
Alnylam Pharmaceuticals
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $284 → $268
Current: $251.15
Upside: +6.71%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $2.11
Upside: +847.87%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $1.19
Upside: +1,748.74%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $10.45
Upside: +177.51%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $3.89
Upside: +79.95%
Karyopharm Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $75 → $54
Current: $6.02
Upside: +797.76%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $1.75
Upside: +1,042.86%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20 → $5
Current: $5.15
Upside: -2.91%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.62
Upside: +517.28%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $39.85
Upside: +140.90%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $11.41
Upside: +355.74%
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $97.17
Upside: +18.35%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $44.27
Upside: +28.76%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $13.03
Upside: +107.21%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.04
Upside: +573.08%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $32.30
Upside: +48.63%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $5.08
Upside: +431.50%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $3.26
Upside: +513.50%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $6.99
Upside: +543.78%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.71
Upside: +1,308.45%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $0.33
Upside: +2,339.02%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.13
Upside: +40.85%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.09
Upside: +489.97%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $1.13
Upside: +2,554.87%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $6.67
Upside: +575.17%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $0.32
Upside: +6,171.56%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $35.11
Upside: +127.86%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $5.99
Upside: +150.63%